Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene Therapeutics (ALLO) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Tuesday, 28'th Feb 2023
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 7.04% and 6%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
08:30am, Tuesday, 21'st Feb 2023
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:17am, Wednesday, 15'th Feb 2023
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Biotech Stocks Set to Outpace Q4 Earnings Estimates
03:48pm, Friday, 03'rd Feb 2023
Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.
Allogene Therapeutics (ALLO) Soars 15.7%: Is Further Upside Left in the Stock?
04:31am, Wednesday, 25'th Jan 2023
Allogene Therapeutics (ALLO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
04:05pm, Tuesday, 17'th Jan 2023
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:30am, Wednesday, 04'th Jan 2023
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Down -41.38% in 4 Weeks, Here's Why Allogene Therapeutics (ALLO) Looks Ripe for a Turnaround
11:17am, Thursday, 29'th Dec 2022
Allogene Therapeutics (ALLO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin
Allogene: Pioneering Allogeneic CAR-T Developer With No Near-Term Catalysts
03:27pm, Friday, 02'nd Dec 2022
Allogene Therapeutics, Inc. has an excellent pedigree and superior science. However, with it being a leader in a difficult field, investing in Allogene Therapeutics, Inc. here is tough.
Top 10 most-shorted stocks as of November 2022
11:18am, Wednesday, 30'th Nov 2022
The difficult state of the macroeconomic environment in 2022 has had a negative impact on the performance of a number of equity investments. Worries about a recession and a bearish attitude among inve
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
08:30am, Wednesday, 09'th Nov 2022
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3
02:18pm, Thursday, 03'rd Nov 2022
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.
Allogene Therapeutics, Inc. (ALLO) Q3 2022 Earnings Call Transcript
11:30pm, Wednesday, 02'nd Nov 2022
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Christine Cassiano - CCO David Chang - President and CEO Rafael Amado - EVP
Allogene Therapeutics (ALLO) Reports Q3 Loss, Lags Revenue Estimates
06:52pm, Wednesday, 02'nd Nov 2022
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 6.45% and 45.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
08:30am, Wednesday, 26'th Oct 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
